Physician profile
Eric J Miller
NPI 1417958976
$10,538.14
in general payments reported to CMS, 2019-2025
52 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $1,409 · 2021: $2,084 · 2022: $2,199 · 2023: $2,086 · 2024: $1,144 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,240 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,240.33 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,488.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,171.51 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,123.50 | 2019-2025 | |
| Novo Nordisk INC | $800.48 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $750.80 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.49 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $688.78 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $370.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $313.44 | 2020-2023 | |
| Amgen INC. | $279.21 | 2019-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.04 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $232.25 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $217.87 | 2019-2024 | Xarelto |
| Allergan, INC. | $172.04 | 2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.